CRVS
Price
$7.04
Change
-$0.61 (-7.97%)
Updated
Oct 17 closing price
Capitalization
524.58M
12 days until earnings call
TARA
Price
$5.49
Change
-$0.29 (-5.02%)
Updated
Oct 17 closing price
Capitalization
211.81M
12 days until earnings call
Interact to see
Advertisement

CRVS vs TARA

Header iconCRVS vs TARA Comparison
Open Charts CRVS vs TARABanner chart's image
Corvus Pharmaceuticals
Price$7.04
Change-$0.61 (-7.97%)
Volume$989.99K
Capitalization524.58M
Protara Therapeutics
Price$5.49
Change-$0.29 (-5.02%)
Volume$334.77K
Capitalization211.81M
CRVS vs TARA Comparison Chart in %
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TARA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRVS vs. TARA commentary
Oct 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRVS is a Hold and TARA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 19, 2025
Stock price -- (CRVS: $7.04 vs. TARA: $5.49)
Brand notoriety: CRVS and TARA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRVS: 129% vs. TARA: 71%
Market capitalization -- CRVS: $524.58M vs. TARA: $211.81M
CRVS [@Biotechnology] is valued at $524.58M. TARA’s [@Biotechnology] market capitalization is $211.81M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRVS’s FA Score shows that 0 FA rating(s) are green whileTARA’s FA Score has 1 green FA rating(s).

  • CRVS’s FA Score: 0 green, 5 red.
  • TARA’s FA Score: 1 green, 4 red.
According to our system of comparison, TARA is a better buy in the long-term than CRVS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRVS’s TA Score shows that 3 TA indicator(s) are bullish while TARA’s TA Score has 6 bullish TA indicator(s).

  • CRVS’s TA Score: 3 bullish, 5 bearish.
  • TARA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, TARA is a better buy in the short-term than CRVS.

Price Growth

CRVS (@Biotechnology) experienced а +1.59% price change this week, while TARA (@Biotechnology) price change was +5.17% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +15.88%, and the average quarterly price growth was +79.09%.

Reported Earning Dates

CRVS is expected to report earnings on Oct 30, 2025.

TARA is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRVS($525M) has a higher market cap than TARA($212M). CRVS YTD gains are higher at: 31.589 vs. TARA (3.977). CRVS has higher annual earnings (EBITDA): -35.45M vs. TARA (-57.01M). TARA has more cash in the bank: 122M vs. CRVS (74.4M). CRVS has less debt than TARA: CRVS (1.08M) vs TARA (3.95M). CRVS (0) and TARA (0) have equivalent revenues.
CRVSTARACRVS / TARA
Capitalization525M212M248%
EBITDA-35.45M-57.01M62%
Gain YTD31.5893.977794%
P/E RatioN/AN/A-
Revenue00-
Total Cash74.4M122M61%
Total Debt1.08M3.95M27%
FUNDAMENTALS RATINGS
CRVS vs TARA: Fundamental Ratings
CRVS
TARA
OUTLOOK RATING
1..100
735
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
16
Undervalued
PROFIT vs RISK RATING
1..100
73100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
3735
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TARA's Valuation (16) in the null industry is somewhat better than the same rating for CRVS (67) in the Pharmaceuticals Major industry. This means that TARA’s stock grew somewhat faster than CRVS’s over the last 12 months.

CRVS's Profit vs Risk Rating (73) in the Pharmaceuticals Major industry is in the same range as TARA (100) in the null industry. This means that CRVS’s stock grew similarly to TARA’s over the last 12 months.

TARA's SMR Rating (97) in the null industry is in the same range as CRVS (98) in the Pharmaceuticals Major industry. This means that TARA’s stock grew similarly to CRVS’s over the last 12 months.

TARA's Price Growth Rating (35) in the null industry is in the same range as CRVS (37) in the Pharmaceuticals Major industry. This means that TARA’s stock grew similarly to CRVS’s over the last 12 months.

CRVS's P/E Growth Rating (99) in the Pharmaceuticals Major industry is in the same range as TARA (100) in the null industry. This means that CRVS’s stock grew similarly to TARA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRVSTARA
RSI
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
68%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 10 days ago
80%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 12 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TARA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ARYEX26.740.20
+0.75%
American Century Real Estate Y
DLACX16.540.08
+0.49%
BNY Mellon Large Cap Equity Y
JCMAX65.040.16
+0.25%
JPMorgan Mid Cap Equity A
FGFCX41.59N/A
N/A
Federated Hermes International Leaders C
GOCAX15.40-0.15
-0.96%
Gabelli International Small Cap A

CRVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRVS has been loosely correlated with SYRE. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if CRVS jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRVS
1D Price
Change %
CRVS100%
-7.97%
SYRE - CRVS
44%
Loosely correlated
+1.03%
IPSC - CRVS
42%
Loosely correlated
-2.60%
RZLT - CRVS
41%
Loosely correlated
-2.03%
TERN - CRVS
41%
Loosely correlated
-2.32%
KRRO - CRVS
37%
Loosely correlated
-13.27%
More

TARA and

Correlation & Price change

A.I.dvisor indicates that over the last year, TARA has been loosely correlated with BRNS. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if TARA jumps, then BRNS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TARA
1D Price
Change %
TARA100%
-5.02%
BRNS - TARA
34%
Loosely correlated
-1.33%
ITRM - TARA
33%
Poorly correlated
-3.86%
SRRK - TARA
32%
Poorly correlated
-5.10%
CDIO - TARA
31%
Poorly correlated
-1.04%
CRVS - TARA
31%
Poorly correlated
-7.97%
More